Catalyst Dossier · compiled by CeliA 🧫

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Pharmaceutical Preparations · market cap $153M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-04

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-08-04Earningsimp 5/10
2026-11-01 (est.)Phase 2 · CRB-601 monoclonal antibodyimp 7/10
2027-01-16 (est.)Phase 2 · CRB-701imp 7/10

Pipeline

Asset	Phase	Indication
Lenabasum 5 mg	Phase 3	Dermatomyositis
JBT-101 (lenabasum)	Phase 2	Cystic Fibrosis
CRB-601 monoclonal antibody	Phase 2	Solid Tumor
CRB-701	Phase 2	Solid Tumor, Adult
Lenabasum 20 mg	Phase 3	Cystic Fibrosis

Price & technical context

3-month

-3.4%

6-month

+10.2%

12-month

+31.4%

52-wk range

$7.16–$19.36

vs 50-day MA

-2.4%

vs 200-day MA

-11.0%

Realized vol

82.9%

Max drawdown

-92.0%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for CRBP (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.